JP2025503967A5 - - Google Patents
Info
- Publication number
- JP2025503967A5 JP2025503967A5 JP2024544442A JP2024544442A JP2025503967A5 JP 2025503967 A5 JP2025503967 A5 JP 2025503967A5 JP 2024544442 A JP2024544442 A JP 2024544442A JP 2024544442 A JP2024544442 A JP 2024544442A JP 2025503967 A5 JP2025503967 A5 JP 2025503967A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- receptor
- item
- immune cell
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304409P | 2022-01-28 | 2022-01-28 | |
| US63/304,409 | 2022-01-28 | ||
| PCT/US2023/011698 WO2023147019A2 (en) | 2022-01-28 | 2023-01-27 | Compositions and methods for treating mesothelin positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503967A JP2025503967A (ja) | 2025-02-06 |
| JP2025503967A5 true JP2025503967A5 (https=) | 2026-01-30 |
Family
ID=87472570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544442A Pending JP2025503967A (ja) | 2022-01-28 | 2023-01-27 | メソテリン陽性がんを処置するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250269027A1 (https=) |
| EP (1) | EP4469559A4 (https=) |
| JP (1) | JP2025503967A (https=) |
| KR (1) | KR20240155391A (https=) |
| CN (1) | CN119403921A (https=) |
| AU (1) | AU2023213691A1 (https=) |
| CA (1) | CA3243381A1 (https=) |
| IL (1) | IL314114A (https=) |
| MX (1) | MX2024009338A (https=) |
| WO (1) | WO2023147019A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025030141A1 (en) * | 2023-08-02 | 2025-02-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating cancers with hla-a*03 loss of expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504696A (zh) * | 2017-09-15 | 2019-03-22 | 上海恒润达生生物科技有限公司 | 靶向人源化mesothelin的嵌合抗原受体的方法和用途 |
| BR112021006100A2 (pt) * | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| CA3132458A1 (en) * | 2019-03-15 | 2020-09-24 | Rutgers, The State University Of New Jersey | Cd147 chimeric antigen receptors and methods of use |
| SG11202112676VA (en) * | 2019-05-16 | 2021-12-30 | Memorial Sloan Kettering Cancer Center | Mesothelin cars and uses thereof |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| CN115052887B (zh) * | 2019-12-11 | 2026-03-31 | A2生物治疗公司 | 基于lilrb1的嵌合抗原受体 |
| IL300500A (en) * | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
-
2023
- 2023-01-27 AU AU2023213691A patent/AU2023213691A1/en active Pending
- 2023-01-27 WO PCT/US2023/011698 patent/WO2023147019A2/en not_active Ceased
- 2023-01-27 US US18/833,321 patent/US20250269027A1/en active Pending
- 2023-01-27 EP EP23747631.2A patent/EP4469559A4/en active Pending
- 2023-01-27 JP JP2024544442A patent/JP2025503967A/ja active Pending
- 2023-01-27 CN CN202380031880.6A patent/CN119403921A/zh active Pending
- 2023-01-27 IL IL314114A patent/IL314114A/en unknown
- 2023-01-27 KR KR1020247028607A patent/KR20240155391A/ko active Pending
- 2023-01-27 MX MX2024009338A patent/MX2024009338A/es unknown
- 2023-01-27 CA CA3243381A patent/CA3243381A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538115A5 (https=) | ||
| CN109153723B (zh) | 抗pd-1抗体与放射的组合治疗癌症 | |
| IL300500A (en) | Preparations and methods for the treatment of mesothelin positive cancer | |
| TWI454260B (zh) | 包含專一性辨識ｃｄ３８之抗體及黴法蘭（ｍｅｌｐｈａｌａｎ）之抗腫瘤組合 | |
| TWI436770B (zh) | 包含專一性辨識ｃｄ３８之抗體及阿糖胞苷（ｃｙｔａｒａｂｉｎｅ）之抗腫瘤組合 | |
| JP2023538116A5 (https=) | ||
| JP2020503273A5 (https=) | ||
| JP2023538114A5 (https=) | ||
| JP2024527606A5 (https=) | ||
| CA2947471A1 (en) | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
| CA3136568A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| IL300497A (en) | Compositions and methods for treating CEACAM-positive cancer | |
| JP2022528030A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2021512637A5 (https=) | ||
| IL300629A (en) | Preparations and methods for the treatment of EGFR positive cancer | |
| JP2021534784A5 (https=) | ||
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| EP3692066A2 (en) | Combination treatment for cancer | |
| JP2025503967A5 (https=) | ||
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| JP2022554353A5 (https=) | ||
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) |